NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02746796,Study of ONO-4538 in Gastric Cancer,https://clinicaltrials.gov/study/NCT02746796,,COMPLETED,"The purpose of study is to evaluate the efficacy and safety of ONO-4538 with chemotherapy in unresectable advanced or recurrent gastric cancer (including esophagogastric junction cancer) not previously treated with the first-line therapy. Part 1 is intended to evaluate the tolerability, safety, and efficacy of ONO-4538 in combination with SOX therapy (Tegafur / gimeracil / oteracil potassium + Oxaliplatin) or CapeOX therapy (Capecitabine + Oxaliplatin). In part 2, the investigator or the subinvestigator will choose a chemotherapy (SOX or CapeOX therapy), taking into account the condition of each subject. Part 2 is planned to evaluate the efficacy and safety of ONO-4538 + chemotherapy in comparison with placebo + chemotherapy.",NO,Gastric Cancer,DRUG: ONO-4538|DRUG: Oxaliplatin|DRUG: Tegafur- Gimeracil-Oteracil potassium|DRUG: Capecitabine|DRUG: Placebo,"Progression-free survival (central assessment by IRRC) (only Part 2), Up to study completion (estimated time frame: 48 months)|Overall survival (only Part 2), Up to study completion (estimated time frame: 54 months)","Objective response rate (only Part 2), Up to study completion (estimated time frame: 54 months)|Progression-free survival (assessment by the site investigator)(only Part 2), Up to study completion (estimated time frame: 54 months)|Duration of response (only Part 2), Up to study completion (estimated time frame: 54 months)|Disease control rate (only Part 2), Up to study completion (estimated time frame: 54 months)|Time to response (only Part 2), Up to study completion (estimated time frame: 54 months)|Best overall response (only Part 2), Up to study completion (estimated time frame: 54 months)|Percent change in the sum of diameters of target lesions (only Part 2), Up to study completion (estimated time frame: 54 months)|Safety will be analyzed through the incidence of adverse events, serious adverse events, Up to 28 days from last dose|Safety will be analyzed through the incidence of laboratory abnormalities, Up to 28 days from last dose",,Ono Pharmaceutical Co. Ltd,,ALL,"ADULT, OLDER_ADULT",PHASE2|PHASE3,680,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",ONO-4538-37,2016-03,2020-01,2022-11-17,2016-04-21,,2024-05-03,"Aichi Clinical Site, Nagoya, Aichi, Japan|Aomori Clinical Site, Hirosaki, Aomori, Japan|Aomori Clinical Site, Misawa, Aomori, Japan|Chiba Clinical Site, Funabashi, Chiba, Japan|Chiba Clinical Site, Kamogawa, Chiba, Japan|Chiba Clinical Site, Kashiwa, Chiba, Japan|Ehime Clinical Site1, Matsuyama, Ehime, Japan|Ehime Clinical Site2, Matsuyama, Ehime, Japan|Fukuoka Clinical Site, Iizuka, Fukuoka, Japan|Fukuoka Clinical Site1, Kitakyushu, Fukuoka, Japan|Fukuoka Clinical Site2, Kitakyushu, Fukuoka, Japan|Fukuoka Clinical Site, Kurume, Fukuoka, Japan|Gifu Clinical Site, Gifu-shi, Gifu, Japan|Gifu Clinical Site, Ogaki, Gifu, Japan|Gumma Clinical Site, Maebashi, Gumma, Japan|Gumma Clinical Site, Takasaki, Gumma, Japan|Gunma Clinical Site, Ota, Gunma, Japan|Hiroshima Clinical Site, Kure, Hiroshima, Japan|Hokkaido Clinical Site, Hakodate, Hokkaido, Japan|Hokkaido Clinical Site4, Sapporo-shi, Hokkaido, Japan|Hokkaido Clinical Site1, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site2, Sapporo, Hokkaido, Japan|Hokkaido Clinical Site3, Sapporo, Hokkaido, Japan|Hyogo Clinical Site, Akashi, Hyogo, Japan|Hyogo Clinical Site, Amagasaki, Hyogo, Japan|Hyogo Clinical Site, Kobe, Hyogo, Japan|Hyogo Clinical Site, Nishinomiya, Hyogo, Japan|Ibaraki Clinical Site, Higashiibaraki-gun, Ibaraki, Japan|Ibaraki Clinical Site, Tsuchiura-shi, Ibaraki, Japan|Ishikawa Clinical Site1, Kanazawa, Ishikawa, Japan|Ishikawa Clinical Site2, Kanazawa, Ishikawa, Japan|Iwate Clinical Site, Morioka, Iwate, Japan|Kagawa Clinical Site, Kita-gun, Kagawa, Japan|Kanagawa Clinical Site, Isehara, Kanagawa, Japan|Kanagawa Clinical Site, Kamakura, Kanagawa, Japan|Kanagawa Clinical Site, Sagamihara, Kanagawa, Japan|Kanagawa Clinical Site1, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site2, Yokohama, Kanagawa, Japan|Kanagawa Clinical Site3, Yokohama, Kanagawa, Japan|Miyagi Clinical Site, Natori, Miyagi, Japan|Miyagi Clinical Site, Osaki, Miyagi, Japan|Miyagi Clinical Site, Sendai-shi, Miyagi, Japan|Nagano Clinical Site, Saku, Nagano, Japan|Nara Clinical Site, Ikoma, Nara, Japan|Nara Clinical Site, Kashihara-shi, Nara, Japan|Okayama Clinical Site, Kurashiki, Okayama, Japan|Osaka Clinical Site, Izumi, Osaka, Japan|Osaka Clinical Site, Osakasayama, Osaka, Japan|Osaka Clinical Site, Sakai, Osaka, Japan|Osaka Clinical Site, Suita, Osaka, Japan|Osaka Clinical Site, Takatsuki, Osaka, Japan|Osaka Clinical Site, Toyonaka, Osaka, Japan|Saitama Clinical Site, Hidaka, Saitama, Japan|Saitama Clinical Site, Kitaadachi-gun, Saitama, Japan|Shizuoka Clinical Site, Hamamatsu-shi, Shizuoka, Japan|Tochigi Clinical Site, Shimotsuke, Tochigi, Japan|Tochigi Clinical Site, Utsunomiya, Tochigi, Japan|Tokyo Clinical Site, Bunkyo-ku, Tokyo, Japan|Tokyo Clinical Site, Chuo-ku, Tokyo, Japan|Tokyo Clinical Site, Fuchu, Tokyo, Japan|Tokyo Clinical Site, Koto-ku, Tokyo, Japan|Tokyo Clinical Site, Minato-ku, Tokyo, Japan|Tokyo Clinical Site, Shinagawa-ku, Tokyo, Japan|Tokyo Clinical Site1, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site2, Shinjuku-ku, Tokyo, Japan|Tokyo Clinical Site, Tachikawa, Tokyo, Japan|Tottori Clinical Site, Yonago, Tottori, Japan|Yamagata Clinical Site, Sakata, Yamagata, Japan|Akita Clinical Site, Akita, Japan|Chiba Clinical Site1, Chiba, Japan|Chiba Clinical Site2, Chiba, Japan|Fukui Clinical Site, Fukui, Japan|Fukuoka Clinical Site1, Fukuoka, Japan|Fukuoka Clinical Site2, Fukuoka, Japan|Fukuoka Clinical Site3, Fukuoka, Japan|Fukuoka Clinical Site4, Fukuoka, Japan|Fukushima Clinical Site, Fukushima, Japan|Hiroshima Clinical Site1, Hiroshima, Japan|Hiroshima Clinical Site2, Hiroshima, Japan|Hiroshima Clinical Site3, Hiroshima, Japan|Kumamoto Clinical Site1, Kumamoto, Japan|Kumamoto Clinical Site2, Kumamoto, Japan|Kumamoto Clinical Site3, Kumamoto, Japan|Kyoto Clinical Site1, Kyoto, Japan|Kyoto Clinical Site2, Kyoto, Japan|Kyoto Clinical Site3, Kyoto, Japan|Niigata Clinical Site, Niigata, Japan|Okayama Clinical Site, Okayama, Japan|Osaka Clinical Site1, Osaka, Japan|Osaka Clinical Site2, Osaka, Japan|Osaka Clinical Site3, Osaka, Japan|Osaka Clinical Site4, Osaka, Japan|Shizuoka Clinical Site, Shizuoka, Japan|Tokushima Clinical Site, Tokushima, Japan|Toyama Clinical Site, Toyama, Japan|Wakayama Clinical Site, Wakayama, Japan|Yamagata Clinical Site, Yamagata, Japan|Busan Clinical Site, Busan, Korea, Republic of|Daegu Clinical Site 1, Daegu, Korea, Republic of|Daegu Clinical Site 2, Daegu, Korea, Republic of|Daejeon Clinical Site, Daejeon, Korea, Republic of|Gyeonggi-Do Clinical Site1, Gyeonggi-Do, Korea, Republic of|Gyeonggi-Do Clinical Site2, Gyeonggi-Do, Korea, Republic of|Gyeonggi-Do Clinical Site3, Gyeonggi-Do, Korea, Republic of|Gyeonggi-Do Clinical Site4, Gyeonggi-Do, Korea, Republic of|Gyeonggi-Do Clinical Site5, Gyeonggi-Do, Korea, Republic of|Gyeongnam Clinical Site, Gyeongnam, Korea, Republic of|Incheon Clinical Site, Incheon, Korea, Republic of|Jeollabuk-Do Clinical Site, Jeollabuk-Do, Korea, Republic of|Jeollanam-do Clinical Site, Jeollanam-do, Korea, Republic of|Seoul Clinical Site 1, Seoul, Korea, Republic of|Seoul Clinical Site 2, Seoul, Korea, Republic of|Seoul Clinical Site 3, Seoul, Korea, Republic of|Seoul Clinical Site 4, Seoul, Korea, Republic of|Seoul Clinical Site 5, Seoul, Korea, Republic of|Seoul Clinical Site 6, Seoul, Korea, Republic of|Seoul Clinical Site7, Seoul, Korea, Republic of|Seoul Clinical Site8, Seoul, Korea, Republic of|Seoul Clinical Site9, Seoul, Korea, Republic of|Ulsan Clinical Site, Ulsan, Korea, Republic of|Kaohsiung Clinical Site1, Kaohsiung, Taiwan|Kaohsiung Clinical Site2, Kaohsiung, Taiwan|New Taipei Clinical Site 1, New Taipei, Taiwan|Taichung Clinical Site 1, Taichung, Taiwan|Taichung Clinical Site2, Taichung, Taiwan|Tainan Clinical Site1, Tainan, Taiwan|Tainan Clinical Site2, Tainan, Taiwan|Taipei Clinical Site1, Taipei, Taiwan|Taipei Clinical Site2, Taipei, Taiwan|Taoyuan Clinical Site, Taoyuan, Taiwan",
